PMG
CORT icon

ProVise Management Group’s Corcept Therapeutics CORT Stock Holding History

ProVise Management Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-47,980
Closed -$1.04M – 347
2023
Q1 		$1.04M Buy
+47,980
New +$1.05M 0.1% 164

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

ProVise Management Group's CORT Position: Q2 2023 in Review

ProVise Management Group sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 47,980 shares — an estimated $1.04M sold.

ProVise Management Group first reported a position in CORT in Q1 2023 and held it in 1 quarter. The position peaked at $1.04M in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

  • ProVise Management Group reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
  • ProVise Management Group sold 47,980 Corcept Therapeutics shares in Q2 2023, an estimated $1.04M.
  • ProVise Management Group first reported a position in Corcept Therapeutics in Q1 2023 and held it in 1 quarter.
  • ProVise Management Group's Corcept Therapeutics position peaked at $1.04M in Q1 2023.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on ProVise Management Group's 13F filing for Q2 2023, filed 3 Aug 2023.